Substantial intraindividual variability of BNP concentrations in patients with hypertension

被引:18
作者
Conen, D.
Pfisterer, M.
Martina, B.
机构
[1] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Med Outpatient Clin, CH-4031 Basel, Switzerland
关键词
brain natriuretic peptide; hypertension; risk assessment;
D O I
10.1038/sj.jhh.1001988
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Plasma concentrations of B-type natriuretic peptides (BNP) independently predict the risk of death and cardiovascular events. In the present study, we investigated the intraindividual variability of BNP concentrations, a potential confounder of risk prediction. Consecutive outpatients with blood pressure (BP) values of at least 140/90 mmHg and not taking BP lowering therapy were asked to participate. Exclusion criteria were renal insufficiency, structural heart disease on echocardiography, except left ventricular hypertrophy and any other severe concomitant illness. Plasma BNP levels were determined on two different days using the same assay. In total, 77 patients were included. Mean age was 54 +/- 12 years, 55% were male and mean systolic/diastolic BP was 163 +/- 16/96 +/- 8 mmHg. Mean creatinine was 70 +/- 14 mu mol/l. The median interval between the two BNP assays was 10 days (interquartile range 1-23 days). Median BNP concentrations were 17 and 16 pg/ml for the first and second visit, respectively (P = 0.48). However, there was a wide range of differences in BNP values among individual patients, 34 patients (44%) having an absolute difference of at least 10 pg/ml. When patients were categorized according to tertiles of BNP levels, 25 (32%) changed from one tertile at the first visit to another at the second visit. In conclusion, these data indicate that BNP levels may be used on a population level. However, the high intraindividual variability seems to preclude useful risk stratification in the individual patient. Care should be taken in the interpretation of single BNP values below the currently accepted thresholds for heart failure.
引用
收藏
页码:387 / 391
页数:5
相关论文
共 20 条
[1]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[2]   High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure [J].
Bruins, S ;
Fokkema, MR ;
Römer, JWP ;
DeJongste, MJL ;
Van der Dijs, FPL ;
Van den Ouewland, JMW ;
Muskiet, FAJ .
CLINICAL CHEMISTRY, 2004, 50 (11) :2052-2058
[3]  
d'Eril GVM, 2003, CLIN CHEM, V49, P1554
[4]   Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy [J].
Dahlof, B ;
Zanchetti, A ;
Diez, J ;
Nicholls, MG ;
Yu, CM ;
Barrios, V ;
Aurup, P ;
Smith, RD ;
Johansson, M .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1855-1864
[5]  
Deary AJ, 2002, CLIN SCI, V103, P493
[6]   BRAIN NATRIURETIC PEPTIDE AS A CARDIAC HORMONE IN ESSENTIAL-HYPERTENSION [J].
KOHNO, M ;
HORIO, T ;
YOKOKAWA, K ;
MURAKAWA, KI ;
YASUNARI, K ;
AKIOKA, K ;
TAHARA, A ;
TODA, I ;
TAKEUCHI, K ;
KURIHARA, N ;
TAKEDA, T .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 (01) :29-34
[7]   Effect of compensated renal dysfunction on approved heart failure markers -: Direct comparison of brain natriuretic peptide (BNP) and N-terminal Pro-BNP [J].
Luchner, A ;
Hengstenberg, C ;
Löwel, H ;
Riegger, GAJ ;
Schunkert, H ;
Holmer, S .
HYPERTENSION, 2005, 46 (01) :118-123
[8]   Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure [J].
Maisel, AS ;
Krishnaswamy, P ;
Nowak, RM ;
McCord, J ;
Hollander, JE ;
Duc, P ;
Omland, T ;
Storrow, AB ;
Abraham, WT ;
Wu, AHB ;
Clopton, P ;
Steg, PG ;
Westheim, A ;
Knudsen, CW ;
Perez, A ;
Kazanegra, R ;
Herrmann, HC ;
McCullough, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) :161-167
[9]   2003 European society of hypertension -: European Society of Cardiology guidelines for the management of arterial hypertension [J].
Mancia, G ;
Rosei, EA ;
Cifkova, R ;
DeBacker, G ;
Erdine, S ;
Fagard, R ;
Farsang, C ;
Heagerty, AM ;
Kawecka-Jaszcs, K ;
Kiowski, W ;
Kjeldsen, S ;
Lüscher, T ;
McInnes, G ;
Mallion, JM ;
Brien, EO ;
Poulter, NR ;
Priori, SG ;
Rahn, KH ;
Rodicio, JL ;
Ruilope, LM ;
Safar, M ;
Staessen, JA ;
van Zwieten, P ;
Waeber, B ;
Williams, B ;
Zanchetti, A ;
Zannad, F .
JOURNAL OF HYPERTENSION, 2003, 21 (06) :1011-1053
[10]   Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea [J].
Mueller, C ;
Scholer, A ;
Laule-Kilian, K ;
Martina, B ;
Schindler, C ;
Buser, P ;
Pfisterer, M ;
Perruchoud, AP .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :647-654